Burning Rock Biotech Ltd
No SEC Form 4 filings for $BNR in the last 30 days.
See all $BNR insider activity →Burning Rock Biotech (BNR) reported Q2 2026 revenue of RMB134.8M, down 9% YoY. In-hospital business revenue grew to RMB67.1M, while central lab and pharma R&D services declined. Gross profit was RMB97.8M, with a gross margin of 72.6%. Net loss was RMB18.4M. The company expects regulatory progress and new product approvals to drive long-term growth. BNR stock is currently at $12.17, up 1.49%.
Burning Rock Biotech Limited (BNR) reported a wider Q1 loss of -RMB18.41 million, or -RMB0.17 per share, compared to -RMB9.70 million, or -RMB0.09 per share, a year ago. Revenue declined 9.3% to RMB134.77 million from RMB148.55 million.
Burning Rock Biotech (NASDAQ: BNR) reported Q2 2026 revenues of RMB134.7M (US$19.9M), down 9.3% YoY. Central lab revenue fell 10%, while in-hospital revenue rose 7.4%. Gross profit decreased 9.5% to RMB97.8M. The company expects new product approvals to drive future growth. Cash reserves stood at RMB419.1M as of June 30, 2026.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BNR (Burning Rock Biotech Ltd). Coverage has skewed bearish: 0 bullish, 0 neutral, and 3 bearish.
Recent BNR coverage spans earnings, financial news and insider activity.
Earnings miss and higher loss may pressure the stock short‑term.
Burning Rock Biotech Limited (BNR) reported a wider Q1 loss of -RMB18.41 million, or -RMB0.17 per share, compared to -RMB9.70 million, or -RMB0.09 per share, a year ago. Revenue declined 9.3% to RMB134.77 million from RMB148.55 million.
Earnings miss and mixed segment performance may pressure the stock short term.
Earnings miss and lower pharma services revenue may pressure the stock, while in‑hospital revenue growth offers a modest upside.
Insider open-market buying by a director is a modest bullish signal, but it is not a new fundamental catalyst like earnings or guidance.
AlphAI scores every news story that mentions BNR with an AI model for sentiment and relevance, and aggregates insider trades from Burning Rock Biotech Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Burning Rock Biotech (BNR) reported Q2 2026 revenue of RMB134.8M, down 9% YoY. In-hospital business revenue grew to RMB67.1M, while central lab and pharma R&D services declined. Gross profit was RMB97.8M, with a gross margin of 72.6%. Net loss was RMB18.4M. The company expects regulatory progress and new product approvals to drive long-term growth. BNR stock is currently at $12.17, up 1.49%.
2 min readBurning Rock Biotech Limited (BNR) reported a wider Q1 loss of -RMB18.41 million, or -RMB0.17 per share, compared to -RMB9.70 million, or -RMB0.09 per share, a year ago. Revenue declined 9.3% to RMB134.77 million from RMB148.55 million.
2 min readBurning Rock Biotech (NASDAQ: BNR) reported Q2 2026 revenues of RMB134.7M (US$19.9M), down 9.3% YoY. Central lab revenue fell 10%, while in-hospital revenue rose 7.4%. Gross profit decreased 9.5% to RMB97.8M. The company expects new product approvals to drive future growth. Cash reserves stood at RMB419.1M as of June 30, 2026.
2 min readBurning Rock Biotech Ltd (BNR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Burning Rock Reports Second Quarter 2026 Financial Results GUANGZHOU, China, September 10, 2026—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the fie
2 min readHan Yusheng purchased 731,410 shares of Burning Rock Biotech Ltd (BNR) at an average of $8.45 ($7.45–$9.25, $6.18M total) across 7 trades over 2026-06-11 to 2026-06-26.
2 min readBurning Rock Biotech Limited (NASDAQ: BNR) said founder/CEO/chairman Yusheng Han bought 73,141 ADSs for $618,217.72 from the open market. The company added that, combined with 72,733 ADSs bought in the last two post-earnings windows, Han has bought 145,874 ADSs for $1,976,542.90 across three windows, subject to insider-trading rules.
2 min readThe article says several small- and midcap U.S.-listed Chinese stocks, including Here Group, Zepp Health, Burning Rock Biotech and So-Young International, surged in 2025 but have largely retraced gains in 2026. It links the rally-and-reversal to investor interest in undervaluation and to U.S. scrutiny of suspected stock manipulation. It also notes Nasdaq rules requiring $25m minimum proceeds for new Chinese listings and delisting if value falls below $5m.
7 min readBurning Rock Biotech (BNR) recently reported its Q3 2025 results, showing a reduction in net losses but persistent unprofitability. Despite steady revenue around C¥130 million quarterly and C¥539.3 million trailing 12-month revenue, the company posted a C¥16.8 million loss in Q3 2025, challenging bullish arguments without clearer margin progress. The stock trades at a lower price-to-sales ratio (3.1x) compared to peers, coupled with high share price volatility, highlighting investor concerns about sustained losses.
3 min readGUANGZHOU, China, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Burning Rock Biotech Limited ( NASDAQ: BNR, the "Company" or "Burning Rock" ) , a company focused on the application of next generation sequencing ( NGS ) technology in the field of precision oncology, today reported financial results for the ...
2 min readTOKYO and GUANGZHOU, China, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Riken Genesis Co., Ltd. ( Riken Genesis ) and Burning Rock Biotech Limited BNR "Burning Rock" ) ) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion diagnostic for ...
3 min read
